Colgate-Palmolive Company's Stock Analysis

Colgate-Palmolive Announces Leadership Transition in Legal Department

Jennifer M. Daniels will retire as Chief Legal Officer and Secretary of Colgate-Palmolive Company in 2026. To ensure a smooth transition, the Board of Directors has appointed Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, to succeed Daniels in this role effective June 1, 2026.

Additionally, Jennifer M. Daniels will take on the position of Vice Chair of the Company starting June 1, 2026. This leadership change is aimed at facilitating the transfer of responsibilities within the legal department.

Apr 09, 2026 08:22:52

Colgate-Palmolive Announces Realignment of Operating Segments

Colgate-Palmolive Company is implementing a realignment of its reportable operating segments, effective for the quarter ending March 31, 2026. This change will combine the Europe and Africa/Eurasia regions (excluding Russia and Belarus) with the Skin Health business into a new segment called Europe, Middle East and Africa. Russia and Belarus will be reported under the Asia Pacific segment. This restructuring is part of the company's Strategic Growth and Productivity Program and does not affect historical financial results, cash flows, or financial position.

To assist investors, Colgate-Palmolive has recast its historical geographic segment information to align with the new reporting structure. The company has provided supplemental disclosures and segment information for the years ended December 31, 2025, 2024, and 2023, as well as for the first three quarters of 2025. The recast information is included in Exhibit 99, which should be reviewed alongside the company's Annual Report on Form 10-K for the year ended December 31, 2025.

Mar 17, 2026 16:33:28

Colgate-Palmolive Elects New Board Member, CEO Departure Announced

Colgate-Palmolive Company has elected Christopher S. Boerner, Ph.D., currently the Board Chair and CEO of Bristol-Myers Squibb, to its Board of Directors, effective March 15, 2026. Dr. Boerner brings extensive experience in the pharmaceutical and healthcare industries, having held various leadership roles at Bristol-Myers Squibb and other companies, which may enhance Colgate-Palmolive's strategic direction and oversight.

Additionally, Steven A. Cahillane has announced he will not seek reelection to the Board at the upcoming Annual Meeting of Stockholders on May 8, 2026, due to his new role as CEO of The Kraft Heinz Company. This change in leadership may impact the company's governance structure and investor perception.

Mar 12, 2026 16:33:16

Colgate-Palmolive Reports 2025 Earnings and Cash Returns to Shareholders

Colgate-Palmolive Company announced its financial results for the fourth quarter and full year 2025, reporting a 1.4% increase in net sales and organic sales, despite a 25% decline in GAAP earnings per share (EPS) to $2.63 due to impairment charges related to its skin health business. The company's base business EPS rose 3% to $3.69, and it generated a record $4.2 billion in cash from operations, returning $2.9 billion to shareholders through dividends and share repurchases.

In the fourth quarter, net sales increased by 5.8%, with organic sales up 2.2%, although GAAP EPS fell to $(0.05) due to the same impairment charges. Colgate maintained its market leadership in toothpaste and manual toothbrushes with respective global market shares of 41.3% and 32.4%. For 2026, the company expects net sales growth between 2% and 6%, with organic sales growth of 1% to 4%, alongside anticipated gross profit margin expansion and double-digit EPS growth on a GAAP basis.

Jan 30, 2026 07:57:45

Colgate-Palmolive Issues €600 Million Senior Notes Due 2035

Colgate-Palmolive Company has entered into an underwriting agreement with Barclays Bank PLC and Banco Bilbao Vizcaya Argentaria, S.A. for the issuance and sale of €600,000,000 of its 3.250% Senior Notes, which are due in 2035. This offering is part of the Company's automatic shelf registration statement filed with the SEC on October 27, 2023, and the public offering was initiated on November 3, 2025.

The Notes will be issued under an Indenture with The Bank of New York Mellon as trustee, dated November 15, 1992. A Prospectus Supplement related to this public offering was filed with the SEC on November 5, 2025. The underwriting agreement includes standard representations, warranties, covenants, and indemnification provisions between Colgate-Palmolive and the underwriters.

Nov 10, 2025 16:06:11

Colgate-Palmolive Reports Q3 2025 Earnings and Strategic Initiatives

Colgate-Palmolive Company announced its earnings for the third quarter of 2025, reporting a 2.0% increase in net sales and a flat base business earnings per share of $0.91. The gross profit margin decreased to 59.4%, and net cash provided by operations for the first nine months of 2025 was $2,745 million. The company continues to lead the global market in toothpaste and manual toothbrushes, maintaining market shares of 41.2% and 32.4%, respectively. The company updated its organic sales growth guidance for the year to 1% to 2%, reflecting a negative impact from exiting the private label pet sales business.

Additionally, the Board of Directors has approved a three-year Strategic Growth and Productivity Program aimed at optimizing the organizational structure and global supply chain. This program is expected to incur pre-tax charges between $200 million and $300 million, primarily related to employee and asset-related costs. The initiative is designed to align with the company’s 2030 strategy and is anticipated to enhance growth and efficiency across various regions, including North America and Latin America.

Oct 31, 2025 07:57:12

Colgate-Palmolive Reports Q2 2025 Earnings and Productivity Program

Colgate-Palmolive Company reported a 1.0% increase in net sales and a 2% rise in GAAP earnings per share (EPS) for the second quarter of 2025, with organic sales growing by 1.8%. The company maintained its leadership in the toothpaste and manual toothbrush markets, holding 41.1% and 32.4% global market shares, respectively. For the full year 2025, the company expects net sales to increase by low single digits, with organic sales growth projected at the low end of 2% to 4%, factoring in the exit from private label pet sales and foreign exchange impacts.

Additionally, Colgate-Palmolive's Board of Directors approved a new three-year productivity program aimed at enhancing organizational efficiency and supporting its 2030 strategy. The program is expected to incur pre-tax charges between $200 million and $300 million, with most charges anticipated by the end of 2028. The company plans to streamline its global supply chain and reduce overhead costs as part of this initiative.

Aug 01, 2025 08:00:52

Colgate Reports Q1 2025 Sales Decline Amid Currency Headwinds

Colgate-Palmolive Company reported a 3.1% decrease in net sales for the first quarter of 2025, totaling $4.911 billion. However, organic sales increased by 1.4%, despite a negative impact from lower private label pet volume and a 4.4% headwind from foreign exchange rates. The company’s GAAP earnings per share rose by 2% to $0.85, while base business earnings per share increased by 6% to $0.91. The gross profit margin improved to 60.8%, reflecting an 80 basis point increase compared to the previous year. Net cash provided by operations was reported at $600 million for the quarter. Colgate maintained a strong market share in toothpaste and manual toothbrushes, holding 40.9% and 31.9% globally, respectively.

The company updated its financial guidance for the full year 2025, now expecting net sales to rise by low single digits, with organic sales growth projected between 2% and 4%. The gross profit margin and advertising investment are anticipated to remain relatively flat as a percentage of net sales, with earnings per share expected to increase in the low single digits on both GAAP and non-GAAP bases. Colgate's leadership emphasized their commitment to navigating current market challenges, including tariffs and currency fluctuations, while continuing to invest in brand health.

Apr 25, 2025 07:57:06

Colgate Reports $20 Billion in Net Sales for 2024

Colgate-Palmolive Company announced that it achieved over $20 billion in net sales for the first time, marking a 3.3% increase from the previous year. The company's earnings per share (EPS) rose by 27% to $3.51, and organic sales grew by 7.4%. Additionally, Colgate returned $3.4 billion to shareholders through dividends and share repurchases, while net cash provided by operations increased by 10% compared to 2023.

However, the fourth quarter saw a slight decline in net sales by 0.1%, attributed to lower private label pet volume. Although EPS increased by 3% to $0.90, the company's gross profit margin only slightly improved. Certain divisions, particularly North America and Latin America, faced challenges, with North America reporting a 1% decline in sales and Latin America experiencing a notable 7.2% decrease in net sales, highlighting some regional weaknesses.

Jan 31, 2025 08:00:40

Colgate Reports Strong Growth in Q3 2024 Results

Colgate-Palmolive Company announced positive results for the third quarter of 2024, with net sales rising by 2.4% and organic sales increasing by 6.8%. The company's earnings per share also grew, with GAAP EPS up by 5% to $0.90 and base business EPS up by 6% to $0.91. Additionally, Colgate maintained its leadership in the toothpaste and manual toothbrush markets, holding significant global market shares of 41.6% and 32.3%, respectively. The company is optimistic about its advertising investments, which grew by 16% this quarter, aimed at bolstering brand health and driving further growth.

Despite the overall positive performance, Colgate faced challenges in certain regions, particularly in North America and Latin America, where net sales declined by 2.1% and 3.2%, respectively. The company also acknowledged a negative impact from foreign exchange rates, which affected its sales outlook. However, Colgate remains committed to its strategies for growth, expecting to achieve an organic sales growth of 7% to 8% for the full year 2024, signaling confidence in its operational effectiveness and market strategies.

Oct 25, 2024 08:00:22